Table 3.
Incidence of adverse events (AEs) reported at T1
AEs occurring in >2.5% of all patients | |||
---|---|---|---|
AEs, n (%) | Discontinued treatment (n = 82) | Continued treatment (n = 78) | All patients (n = 160) |
No AEs | 71 (86.5) | 58 (74.3) | 129 (80.6) |
General weakness/fatigue | 3 (3.6) | 10 (12.8) | 13 (8.1) |
Somnolence | 1 (1.2) | 7 (8.9) | 8 (5.0) |
Weight gain | 2 (2.4) | 3 (3.8) | 5 (3.1) |
Hypersalivation | — | 4 (5.1) | 4 (2.5) |
Dizziness | 3 (3.6) | 1 (1.2) | 4 (2.5) |
Data are n (%).